BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 22801729)

  • 1. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
    Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
    Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand.
    Yousefi BH; Manook A; Grimmer T; Arzberger T; von Reutern B; Henriksen G; Drzezga A; Förster S; Schwaiger M; Wester HJ
    ACS Chem Neurosci; 2015 Mar; 6(3):428-37. PubMed ID: 25482310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
    Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamol.
    Snellman A; Rokka J; López-Picón FR; Eskola O; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    EJNMMI Res; 2014; 4():37. PubMed ID: 25977876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
    Nelissen N; Van Laere K; Thurfjell L; Owenius R; Vandenbulcke M; Koole M; Bormans G; Brooks DJ; Vandenberghe R
    J Nucl Med; 2009 Aug; 50(8):1251-9. PubMed ID: 19617318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
    Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
    Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
    Yousefi BH; Manook A; Drzezga A; von Reutern B; Schwaiger M; Wester HJ; Henriksen G
    J Med Chem; 2011 Feb; 54(4):949-56. PubMed ID: 21275403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
    J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of
    Zeydan B; Schwarz CG; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
    J Nucl Med; 2022 Aug; 63(8):1239-1244. PubMed ID: 34916245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 × Tg Alzheimer's Disease Model Mice.
    Kang S; Kim J; Lee SY; Okamura N; Chang KA
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical study on [
    Xu M; Guo J; Gu J; Zhang L; Liu Z; Ding L; Fu H; Ma Y; Liang S; Wang H
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):652-663. PubMed ID: 34292345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of a (18)F-curcumin derivate for β-amyloid plaque imaging.
    Rokka J; Snellman A; Zona C; La Ferla B; Nicotra F; Salmona M; Forloni G; Haaparanta-Solin M; Rinne JO; Solin O
    Bioorg Med Chem; 2014 May; 22(9):2753-62. PubMed ID: 24702859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.